AcrobiosystemsLtd Future Growth
Future criteria checks 4/6
AcrobiosystemsLtd is forecast to grow earnings and revenue by 23.5% and 19.2% per annum respectively. EPS is expected to grow by 23.5% per annum. Return on equity is forecast to be 8.6% in 3 years.
Key information
23.5%
Earnings growth rate
23.5%
EPS growth rate
| Biotechs earnings growth | 34.0% |
| Revenue growth rate | 19.2% |
| Future return on equity | 8.6% |
| Analyst coverage | Good |
| Last updated | 27 Jun 2024 |
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 932 | 264 | 216 | 267 | 5 |
| 12/31/2025 | 802 | 257 | 167 | 210 | 7 |
| 12/31/2024 | 643 | 190 | 116 | 164 | 6 |
| 3/31/2024 | 553 | 139 | -17 | 100 | N/A |
| 12/31/2023 | 544 | 154 | -17 | 111 | N/A |
| 9/30/2023 | 534 | 166 | -158 | 148 | N/A |
| 6/30/2023 | 514 | 186 | -106 | 199 | N/A |
| 3/31/2023 | 497 | 195 | -70 | 209 | N/A |
| 1/1/2023 | 474 | 204 | -82 | 202 | N/A |
| 9/30/2022 | 461 | 219 | 99 | 170 | N/A |
| 6/30/2022 | 438 | 211 | 83 | 149 | N/A |
| 3/31/2022 | 410 | 187 | 85 | 159 | N/A |
| 1/1/2022 | 385 | 174 | 76 | 138 | N/A |
| 9/30/2021 | 351 | 159 | 63 | 119 | N/A |
| 6/30/2021 | 322 | 146 | 83 | 121 | N/A |
| 3/31/2021 | 286 | 135 | 76 | 98 | N/A |
| 12/31/2020 | 246 | 116 | 82 | 96 | N/A |
| 12/31/2019 | 103 | 11 | 10 | 20 | N/A |
| 12/31/2018 | 70 | 11 | -2 | 7 | N/A |
| 12/31/2017 | 47 | 7 | N/A | 2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 301080's forecast earnings growth (23.5% per year) is above the savings rate (2.9%).
Earnings vs Market: 301080's earnings (23.5% per year) are forecast to grow faster than the CN market (22.1% per year).
High Growth Earnings: 301080's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 301080's revenue (19.2% per year) is forecast to grow faster than the CN market (13.6% per year).
High Growth Revenue: 301080's revenue (19.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 301080's Return on Equity is forecast to be low in 3 years time (8.6%).